ClinicaliQ Trial Snapshot
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) — Active Not Recruiting • Phase I / Phase II • NCT03945318.
- BION-1301 was tested for safety and tolerability in healthy people and IgA kidney disease patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN). Conditions: IgA Nephropathy Interventions: BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses, BION-1301 Single Dose Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 103 participants